Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

CRBU

Caribou Biosciences Inc

Mar 06 • 04:00PM ET

1.82

+0.11 6.43 %

Healthcare • Biotechnology • USA • NASD

Peers: EDIT CRSP BEAM NTLA VRTX QURE BLUE PSTX SGMO DTIL

| Held by: VTI VXF IBB SCHA NXTE AVSC DFAC DFAS SCHB XDNA

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-1.59	Insider Own	11.07%	Shs Outstand	95.14M	Perf Week	-4.21%
Market Cap	175.88M	Forward P/E	-	EPS next Y	-1.30	Insider Trans	-0.23%	Shs Float	85.94M	Perf Month	12.35%
Enterprise Value	63.77M	PEG	-	EPS next Q	-0.31	Inst Own	37.80%	Short Float	9.04%	Perf Quarter	-2.15%
Income	-148.12M	P/S	15.76	EPS this Y	22.82%	Inst Trans	-0.01%	Short Ratio	6.50	Perf Half Y	-1.62%
Sales	11.16M	P/B	1.42	EPS next Y	-6.21%	ROA	-59.19%	Short Interest	7.77M	Perf YTD	14.47%
Book/sh	1.28	P/C	1.26	EPS next 5Y	1.71%	ROE	-78.97%	52W High	3.54 -48.51%	Perf Year	56.90%
Cash/sh	1.44	P/FCF	-	EPS past 3/5Y	1.01% -22.62%	ROIC	-99.95%	52W Low	0.66 175.76%	Perf 3Y	-68.62%
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	-6.95% -2.03%	Gross Margin	67.34%	Volatility	7.58% 8.51%	Perf 5Y	-
Dividend TTM	-	EV/Sales	5.71	EPS Y/Y TTM	3.83%	Oper. Margin	-1220.49%	ATR (14)	0.14	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	5.71	Sales Y/Y TTM	11.66%	Profit Margin	-1327.40%	RSI (14)	53.71	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	5.71	EPS Q/Q	28.02%	SMA20	3.94%	Beta	2.55	Target Price	11.75
Payout	-	Debt/Eq	0.22	Sales Q/Q	89.74%	SMA50	10.42%	Rel Volume	1.08	Prev Close	1.71
Employees	97	LT Debt/Eq	0.21	Earnings	Mar 05 AMC	SMA200	0.92%	Avg Volume	1.19M	Price	1.82
IPO	Jul 23, 2021	Option/Short	Yes / Yes	EPS/Sales Surpr.	9.68% 78.57%	Trades		Volume	1,291,721	Change	6.43%

Date	Action	Analyst	Rating Change	Price Target Change
Jun-03-24	Downgrade	Evercore ISI	Outperform → In-line	$13 → $3
Nov-08-23	Initiated	Cantor Fitzgerald	Neutral
Oct-31-23	Initiated	Evercore ISI	Outperform	$13
Jul-11-23	Initiated	Truist	Buy	$23
Feb-18-22	Initiated	RBC Capital Mkts	Outperform	$22
Dec-01-21	Initiated	Oppenheimer	Outperform	$36
Nov-30-21	Initiated	H.C. Wainwright	Buy	$28
Nov-15-21	Upgrade	Citigroup	Neutral → Buy	$27
Aug-17-21	Initiated	SVB Leerink	Outperform	$32
Aug-17-21	Initiated	Citigroup	Neutral	$27
Aug-17-21	Initiated	BofA Securities	Buy	$30

Show Previous Ratings

Mar-05-26 05:15PM	Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Tops Revenue Estimates (Zacks) +6.43%
04:05PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update (GlobeNewswire)
Mar-04-26 08:20AM	EyePoint (EYPT) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
Mar-02-26 09:10AM	Urogen Pharma (URGN) Reports Q4 Loss, Beats Revenue Estimates (Zacks)
Feb-26-26 06:00PM	Syndax Pharmaceuticals (SNDX) Reports Q4 Loss, Tops Revenue Estimates (Zacks)
08:55PM	Loading…
Feb-23-26 08:55PM	Vir Biotechnology, Inc. (VIR) Reports Q4 Loss, Beats Revenue Estimates (Zacks) +6.67% +11.46%
12:06PM	Caribou Biosciences Details Pivotal-Ready Vispa-cel Plan, Flags Need for More Capital at Citi Summit (MarketBeat)
Feb-20-26 12:00PM	Caribou Biosciences (CRBU)'s CB-011 May Reach $734 Million in Peak 2040 Sales, According to Clear Street (Insider Monkey)
10:48AM	Genomics Stocks That Deserve a Place in Your Portfolio in 2026 (Zacks)
Feb-12-26 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-10-26 09:40AM	Is Biohaven Ltd. (BHVN) Stock Outpacing Its Medical Peers This Year? (Zacks)
Feb-04-26 08:00AM	Caribou Biosciences Announces Late-Breaking Presentations at the 2026 Tandem Meetings of ASTCT and CIBMTR (GlobeNewswire)
Jan-13-26 12:00PM	Caribou Biosciences (CRBU) Upgraded to Buy: Here's Why (Zacks)
Dec-01-25 04:05PM	Caribou Biosciences to Host In-Person and Virtual KOL Event at ASH 2025 (GlobeNewswire) -8.76%
Nov-12-25 05:30PM	Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates (Zacks) -12.17%
04:05PM	Loading…
04:05PM	Caribou Biosciences Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Nov-10-25 08:20AM	Septerna, Inc. (SEPN) Reports Q3 Loss, Misses Revenue Estimates (Zacks)
Nov-03-25 05:15PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) -10.70%
07:00AM	Caribou Biosciences Announces Positive Data from CaMMouflage Phase 1 Trial of CB-011 in Multiple Myeloma (GlobeNewswire)
07:00AM	Caribou Biosciences Announces Positive Data from ANTLER Phase 1 Trial Demonstrating Efficacy and Durability of Vispa-cel (CB-010), an Allogeneic CAR-T Cell Therapy, on Par with Autologous CAR-T Cell Therapies (GlobeNewswire)
06:54AM	Caribou results suggest renewed promise for off-the-shelf cancer cell therapy (BioPharma Dive)
Nov-02-25 04:00PM	Caribou Biosciences to Host Webcast to Report New Data Updates from Two Allogeneic CAR-T Cell Therapy Programs in Lymphoma and Multiple Myeloma (GlobeNewswire)
Aug-25-25 04:05PM	Caribou Biosciences to Participate in the Citi 2025 Biopharma Back to School Conference (GlobeNewswire) +6.38%
Aug-12-25 04:05PM	Caribou Biosciences Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire) +8.94%
Jul-31-25 07:20AM	Biogen Inc. (BIIB) Surpasses Q2 Earnings and Revenue Estimates (Zacks)
May-28-25 04:00PM	Caribou Biosciences to Participate in the Jefferies Global Healthcare Conference (GlobeNewswire)
May-13-25 12:00PM	Caribou Biosciences (CRBU) Upgraded to Buy: Here's What You Should Know (Zacks)
May-08-25 05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-06-25 04:00PM	Caribou Biosciences to Participate in the BofA Securities 2025 Health Care Conference (GlobeNewswire) -12.16%
10:01AM	Loading…
May-01-25 10:01AM	Will Clearside Biomedical, Inc. (CLSD) Report Negative Q1 Earnings? What You Should Know (Zacks) -5.77%
Apr-29-25 10:01AM	Will Caribou Biosciences, Inc. (CRBU) Report Negative Q1 Earnings? What You Should Know (Zacks) +10.44%
Apr-25-25 07:50AM	Caribou cuts pipeline and workforce to focus on lead CAR-T programmes (Pharmaceutical Technology) -11.30%
05:00AM	Caribou, in reversal, scraps autoimmune cell therapy and cuts staff (BioPharma Dive)
Apr-24-25 04:15PM	Caribou Biosciences Announces Strategic Pipeline Prioritization with Focus on CB-010 and CB-011 Oncology Programs (GlobeNewswire)
08:10AM	Bristol Myers Squibb (BMY) Surpasses Q1 Earnings and Revenue Estimates (Zacks)
Mar-10-25 05:15PM	Caribou Biosciences, Inc. (CRBU) Reports Q4 Loss, Lags Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update (GlobeNewswire)
Feb-18-25 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire) +5.19%
05:45AM	Shareholders of Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Feb-07-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-31-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - CRBU (PR Newswire) +9.16%
Jan-24-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-17-25 05:45AM	Caribou Biosciences, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-14-25 05:45AM	Investors in Caribou Biosciences, Inc. Should Contact Levi & Korsinsky Before February 24, 2025 to Discuss Your Rights - CRBU (PR Newswire)
Jan-12-25 07:05PM	Caribou Biosciences Initiates the CB-010 GALLOP Phase 1 Trial in Lupus and Provides Outlook for Multiple Clinical Datasets in 2025 (GlobeNewswire)
Jan-07-25 04:00PM	Caribou Biosciences to Present at 43rd Annual J.P. Morgan Healthcare Conference (GlobeNewswire) -8.02%
Jan-02-25 08:00AM	Caribou Biosciences Appoints Sri Ryali as Chief Financial Officer (GlobeNewswire) +5.66%
Dec-30-24 03:01PM	Why Is Caribou Biosciences Inc. (CRBU) Among the Top CRISPR Stocks to Invest In? (Insider Monkey)
Dec-16-24 09:55AM	Caribou Biosciences (CRBU) May Find a Bottom Soon, Here's Why You Should Buy the Stock Now (Zacks)
Nov-20-24 04:00PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Nov-06-24 06:05PM	Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Lags Revenue Estimates (Zacks) +7.42%
04:05PM	Caribou Biosciences Reports Third Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-24 03:53AM	Is Caribou Biosciences (CRBU) a Promising Gene Editing Stock? (Insider Monkey)
Oct-17-24 03:06PM	STATE STREET CORP's Strategic Acquisition in Caribou Biosciences Inc (GuruFocus.com) -5.83%
Sep-25-24 09:00AM	Caribou Biosciences to Present Preclinical Data Supporting Development of CB-010 for Lupus at the American College of Rheumatology Convergence 2024 (GlobeNewswire)
Sep-03-24 08:00AM	Caribou Biosciences Announces the FDA has Granted Fast Track Designations to CB-010 in Refractory SLE and to CB-012 in Relapsed or Refractory AML (GlobeNewswire) -8.33%
Aug-26-24 04:00PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Aug-12-24 08:00AM	Caribou Biosciences Appoints Tina Albertson, MD, PhD, as Chief Medical Officer (GlobeNewswire)
Aug-06-24 06:50PM	Caribou Biosciences, Inc. (CRBU) Reports Q2 Loss, Tops Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports Second Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
10:00AM	Caribou Biosciences, Inc. (CRBU) May Report Negative Earnings: Know the Trend Ahead of Q2 Release (Zacks)
Jul-17-24 07:45AM	Caribou lays off staff; Roche walks away from Relay (BioPharma Dive)
Jul-09-24 08:00AM	Caribou Biosciences Announces Appointment of Terri Laufer, MD, to its Scientific Advisory Board (GlobeNewswire)
Jun-02-24 07:00PM	Caribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
May-30-24 04:01PM	Caribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences (GlobeNewswire)
May-12-24 04:00PM	3 Underappreciated Stocks That Could 10x in 10 Years (InvestorPlace)
May-09-24 05:23AM	Truist Adjusts Price Target on Caribou Biosciences to $19 From $21, Maintains Buy Rating (MT Newswires)
May-07-24 10:55PM	CRBU Stock Earnings: Caribou Biosciences Misses EPS, Misses Revenue for Q1 2024 (InvestorPlace) -6.17%
05:25PM	Caribou Biosciences, Inc. (CRBU) Reports Q1 Loss, Misses Revenue Estimates (Zacks)
04:05PM	Caribou Biosciences Reports First Quarter 2024 Financial Results and Provides Business Update (GlobeNewswire)
May-01-24 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Apr-27-24 06:00AM	Bragar Eagel & Squire is Investigating Certain Officers and Directors of Caribou, Verrica, and Playstudios on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm (GlobeNewswire)
Apr-24-24 10:00AM	Caribou Biosciences to Present Initial Dose Expansion Data from CB-010 ANTLER Phase 1 Trial in r/r B-NHL at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting (GlobeNewswire)
Apr-15-24 09:00AM	Caribou Biosciences Announces Oral Presentation on In Vivo Cas12a chRDNA Genome Editing at the 27th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) (GlobeNewswire)
Apr-04-24 04:00PM	Caribou Biosciences Expands Clinical Development of CB-010 with FDA Clearance of IND in Lupus (GlobeNewswire)
Mar-14-24 12:00PM	All You Need to Know About Caribou Biosciences, Inc. (CRBU) Rating Upgrade to Buy (Zacks)
Mar-13-24 03:32PM	11 Oversold NASDAQ Stocks To Buy Right Now (Insider Monkey) +11.55%
Mar-12-24 12:37PM	Why Caribou Biosciences Stock Is Crashing Today (Motley Fool) -30.47%
Mar-11-24 04:05PM	Caribou Biosciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update (GlobeNewswire)
Mar-05-24 04:30PM	Caribou Biosciences to Present Preclinical Data on CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy, at the American Association for Cancer Research (AACR) Annual Meeting (GlobeNewswire)
Feb-26-24 01:14PM	12 $10 Stocks That Will Triple (Insider Monkey) +6.92%
06:45AM	Missed Out on CRISPR Therapeutics? My Best Gene-Editing Stock to Buy and Hold (Motley Fool)
Feb-23-24 11:25PM	Steven Cohen's Point72 Adds Caribou Biosciences Inc to Its Portfolio (GuruFocus.com)
Feb-15-24 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Feb-12-24 08:30AM	2 Risky Gene-Editing Stocks to Buy in the New Bull Market if You Dare (Motley Fool)
Jan-15-24 08:45AM	3 Biotech Stocks You Can Buy and Hold for the Next Decade (Motley Fool)
Jan-07-24 11:00AM	Caribou Biosciences Appoints Tim Kelly as Chief Technology Officer and Highlights Multiple Clinical Catalysts Expected in 2024 (GlobeNewswire)
Dec-13-23 07:26AM	5 Things to Know Before The Stock Market Opens (Investopedia)
05:20AM	3 Gene-Editing Stocks With the Potential to Mint Millionaires (InvestorPlace)
Dec-12-23 04:02PM	Caribou Biosciences Provides Regulatory Update on CB-010 Pivotal Plan with Phase 3 Trial Initiation Expected by YE 2024 (GlobeNewswire)
Dec-08-23 12:00PM	Caribou Biosciences, Inc. (CRBU) Upgraded to Buy: What Does It Mean for the Stock? (Zacks)
Dec-06-23 09:55AM	Wall Street Analysts Believe Caribou Biosciences, Inc. (CRBU) Could Rally 285.29%: Here's is How to Trade (Zacks)
Nov-20-23 09:55AM	Does Caribou Biosciences, Inc. (CRBU) Have the Potential to Rally 321.46% as Wall Street Analysts Expect? (Zacks) +6.51%
Nov-07-23 04:00PM	Caribou Biosciences Reports Third Quarter 2023 Financial Results and Provides Business Update (GlobeNewswire) -5.03%
Nov-06-23 08:00AM	Caribou Biosciences Announces Appointment of Sundar Jagannath, MD, to its Scientific Advisory Board (GlobeNewswire) +14.11%
Nov-01-23 04:05PM	Caribou Biosciences to Participate in Upcoming Investor Conferences (GlobeNewswire)
Oct-20-23 05:00AM	2 Top Growth Stocks to Buy Right Now Without Hesitation (Motley Fool)
Oct-18-23 08:00AM	Caribou Biosciences Announces FDA Clearance of IND Application for CB-012, an Allogeneic Anti-CLL-1 CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia (GlobeNewswire) -6.00%
Oct-11-23 06:00AM	2 Exciting Biotech Stocks to Buy With Less Than $10 (Motley Fool)

Caribou Biosciences, Inc. engages in the development of an internal pipeline of off-the-shelf CAR-T and CAR-NK cell therapies. Its tools and technologies provide transformative capabilities to basic and applied biological research, therapeutic development, agricultural biotechnology, and industrial biotechnology. The company was founded by Jennifer A. Doudna, Rachel E. Haurwitz, Martin Jinek and James Berger on October 28, 2011 and is headquartered in Berkeley, CA.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Kelly Timothy P	Chief Technology Officer	Feb 25 '26	Sale	1.93	6,228	12,020	73,125	Feb 27 04:01 PM
RUHI AHMAD KHAN	Officer	Feb 24 '26	Proposed Sale	1.96	6,938	13,598		Feb 25 09:42 PM
BARBARA G MCCLUNG	Officer	Feb 24 '26	Proposed Sale	1.96	6,938	13,598		Feb 25 09:41 PM
TIMOTHY KELLY	Officer	Feb 25 '26	Proposed Sale	1.93	6,228	12,051		Feb 25 05:16 PM
Kelly Timothy P	Chief Technology Officer	Feb 24 '26	Sale	1.96	3,147	6,168	79,353	Feb 24 08:54 PM
MCCLUNG BARBARA G	Chief Legal Officer	Feb 24 '26	Sale	1.96	6,938	13,598	481,564	Feb 24 08:54 PM
Khan Ruhi Ahmad	Chief Business Officer	Feb 24 '26	Sale	1.96	6,938	13,598	104,998	Feb 24 08:54 PM
Albertson Tina M.	Chief Medical Officer	Feb 24 '26	Sale	1.96	1,066	2,089	68,523	Feb 24 08:53 PM
Haurwitz Rachel E.	President and CEO	Mar 14 '25	Buy	1.02	20,000	20,400	3,369,395	Mar 17 08:01 AM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CRBU

Caribou Biosciences Inc

Upgrade your FINVIZ experience